title: [Evaluation of prophylactic use of lamivudine in HBV-positive patients with malignant lymphoma undergoing chemotherapy].
abstract: A prospective evaluation was carried out on the effect of lamivudine administration as a prophylactic measure to prevent exacerbation of hepatitis in HBV carrier or chronic hepatitis B patients with malignant lymphoma undergoing chemotherapy. Eighteen patients were registered between 1997 and 2002 from institutions of the Research Group for the Treatment of Malignant Lymphoma. The patients' median age was 53 years old (39-73), and consisted of 8 males and 10 females. HBe-seroconversion had already occurred in 13 and liver biopsy had been performed in 8. No adverse effects of lamivudine were noted and the serum HBV-DNA content did not increase during lamivudine administration. Planned treatment courses could be completed in all patients. In 2, however, the viral load increased and the HBe antibody (Ab) value declined after the cessation of lamivudine, which were reversed to the normal ranges following the resumption of lamivudine. As for the overall outcome, 14 of the patients survived, and there were 4 fatalities due to malignant lymphoma. Serum HBeAb status may be regarded as a useful laboratory marker for deciding the safe cessation of lamivudine. An additional case is described, who had recovered from past HBV infection, but eventually succumbed to fulminant hepatitis after the cessation of lamivudine covering prolonged courses of chemotherapy. This illustrates a need for inclusion of such cases for the prophylactic use of lamivudine.
authors.affiliation: Hematology Division, Showa General Hospital.
authors.forename: Koichi
authors.initials: K
authors.lastname: Kitazume
authors.forename: Hiraku
authors.initials: H
authors.lastname: Mori
authors.forename: Takakazu
authors.initials: T
authors.lastname: Higuchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Shimamoto
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Okumura
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yamanaka
authors.forename: Kazue
authors.initials: K
authors.lastname: Takai
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kura
authors.forename: Umihiko
authors.initials: U
authors.lastname: Sawada
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Omine
authors.forename: Shinsho
authors.initials: S
authors.lastname: Yoshiba
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D002353:Carrier State / Q000175:diagnosis; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood; D006513:Hepatitis B e Antigens / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D017114:Liver Failure, Acute / Q000209:etiology* / Q000517:prevention & control*; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens; D019259:Lamivudine